Controlling bee diseases with non contaminant products is a challenge in apicultural research. Essential oils and their main components have been widely studied as alternative treatments for honeybee pathologies [1, 2, 3]. However, there is little information about prolonged systemic administration. The aim of this study was to evaluate, in laboratory assays, the effect of long term consumption of essential oil...
Aims: To evaluate the cardiovascular (CV) effects of rhEPO treatment in rats under chronic aerobic exercise and to assess the probable cause of sudden death in one rat. Protocol: Male Wistar rats: control - sedentary; rhEPO - 50 IU/Kg/3xwk; swimming (EX) -1 hr, 3x/wk; EX+EPO. Hematology, catecholamines and serotonin, redox status and inflammation, were assessed. One rat of EX+EPO group suffered a sudden death e...
Recombinant human erythropoietin (rhEPO) has been therapeutically used for correction of anaemia. However, due to the increase in circulating red blood cells (RBCs) it promotes, thus increasing oxygen delivery to muscles and improving performance in sport, it has been also illegally used as sports doping. Besides the well known increase of hematocrit and blood viscosity; which might cause serious complications ...
Chronic kidney disease (CKD) is a major public health problem throughout the world. The major outcomes include a rapid progression, with development of anaemia and serious complications, namely thromboembol ic and cardiovascular events. The pathophysiological alterations depend on the CKD degree, which will also determine the moment to initiate hemodialysis and recombinant erythropoietin (rhEPO) therapies Thus,...
Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency degree might determine the moment to start recombinant human EPO (rhEPO) therapy. It has been attributed important non-hematopoietic effects to rhEPO, which might underlie cardio and renoprotectio...
PURPOSE: To evaluate the efficacy of a selective cyclooxygenase-2 (COX-2) inhibitor in rat bladder cancer chemoprevention, as well as to assess the relevance of inflammation, proliferation and oxidative stress in tumor growth and in its prevention. RESULTS: The main findings were: (I) the incidence of carcinoma was: control: 0% (0/8); BBN: 65% (13/20); CEL: 0% (0/8) and BBN + CEL: 12.5% (1/8); (II) the mean tu...
The purpose of this study was to compare the effects of sirolimus (SRL) vs cyclosporine (CsA) concerning the cardiovascular mechanisms hypothetically contributing to hypertension development. Three rat groups were studied: control (vehicle), CsA (5 mg/kg/d), and SRL (1 mg/kg/d). The following parameters were evaluated after 7 weeks of treatment: blood pressured (BP) and heart rate (HR; tail cuff), lipid profile...
The pathophysiological modifications underlying chronic which will determine the moment to start therapy. As there is yet limited information about animal models of moderate chronic renal failure, we intended to perform a complete characterization 60 of the hematological and cardio-renal alterations induced by partial nephrectomy. Blood samples from control and chronic renal failure rats were collected at 0, 3,...
This study aimed to assess the cardio-renal effects of rhEPO therapy on an animal model of moderate chronic renal failure (CRF). Four groups (n =7) of male rat were evaluated during a 12-week follow up period: control; rhEPO: 50 IU/Kg/wk; CRF: two-stage 3/, nephrectomy; CRF+ rhEPO (start after the 3'd wk of surgery). Renal function, haematology and serum inflammation and redox status were assessed. rhEPO treatm...
The purpose of this study was to compare the effects of sirolimus (SRL) vs cyclosporine (CsA) concerning the cardiovascular mechanisms hypothetically contributing to hypertension development. Three rat groups were studied: control (vehicle), CsA (5 mg/kg/d), and SRL (1 mg/kg/d). The following parameters were evaluated after 7 weeks of treatment: blood pressured (BP) and heart rate (HR; tail cuff), lipid profile...
Financiadores do RCAAP | |||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |